Literature DB >> 15606008

[Diagnosis and treatment on osteoradionecrosis of skull base after radiotherapy for nasopharyngeal carcinoma].

Xiao-min Huang1, Yi-qing Zheng, Hai-qiang Mai, Hua Zhou, Xiang Liu, Man-quan Deng, Hua-qing Mi, Geng Xu.   

Abstract

OBJECTIVE: To investigate the diagnosis and management on osteoradionecrosis (ORN) of skull base in the patients with nasopharyngeal carcinoma (NPC) after radiotherapy.
METHODS: All patients (n = 15) diagnosed as NPC and ORN of skull base were studied on the clinical data, diagnosis and therapy.
RESULTS: All the patients were found with foul odor, headache, bleeding and exposed necrotic bone. 9 patients were treated by surgery, among them 2 patients died of temporal lobe radionecrosis, and the survival time of remaining 7 patients was 2 to 7 years. 5 patients with extensive ORN and 1 patient with local ORN were treated by conservative methods, among them 3 died of nasopharyngeal bleeding and 1 died of respiratory and heart failure, survival time of the remaining 2 patients was 3 to 5 years.
CONCLUSIONS: ORN can be diagnosed by clinical characteristics, CT or MR, and endoscopic findings. Surgery is the best choice for ORN. The patients with extensive ORN or radiation-induced cranial neuropathy had poor prognosis. The most common causes of death were nasopharyngeal bleeding and exhaustion.

Entities:  

Mesh:

Year:  2004        PMID: 15606008

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Ke Za Zhi        ISSN: 0412-3948


  2 in total

1.  Treatment Outcomes for Osteoradionecrosis of the Central Skull Base: A Systematic Review.

Authors:  Noah Shaikh; Chadi A Makary; Lindsey Ryan; Camilo Reyes
Journal:  J Neurol Surg B Skull Base       Date:  2021-08-18

2.  Radionecrosis of the frontal lobe as a consequence of malignant ethmoid tumor management: incidence, diagnosis, risk factors, prevention and management.

Authors:  N Oker; P Lang; D Bresson; B George; J-P Guichard; M Wassef; E Sauvaget; S Froelich; R Kania; P Herman
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-16       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.